Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) issued its quarterly earnings data on Tuesday. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen said ALTITUDE-AD remains on track, with top-line Phase II results expected late in 2026 and enrollment/extension transitions proceeding smoothly. Management reiterated that the study is designed to test whether sabirnetug can deliver a differentiated effect by targeting toxic Abeta oligomers rather than amyloid plaques.
• The company highlighted a potentially favorable data package from ALTITUDE-AD, including the primary endpoint (iADRS) plus secondary efficacy, safety, ARIA, and biomarker readouts. Management said a “clear win” would likely require an efficacy signal around 30% slowing or better, along with a compelling risk-benefit profile versus approved anti-amyloid drugs.
• Acumen also emphasized progress in its enhanced brain delivery (EBD) program and said it expects to exercise its option to license two JCR Pharmaceuticals compounds in Q2 2026. The company continues to target an IND filing in mid-2027 and believes the platform could improve brain penetration, distribution, and enable subcutaneous dosing.
• The balance sheet ended the quarter at $128.4 million in cash and marketable securities, which management said should fund operations into early 2027. First-quarter operating results included $16.5 million of R&D expense, $4.7 million of G&A expense, and a $20.7 million net loss.
• Management said site feedback and operational execution on ALTITUDE-AD have been strong, including a relatively fast 10-month enrollment and improved screening using plasma p-tau217 to reduce unnecessary PET scans. They also noted continued physician and KOL interest in sabirnetug and the broader anti-amyloid market despite recent skepticism about the class.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ:ABOS traded up $0.02 during midday trading on Wednesday, hitting $2.50. The company had a trading volume of 46,099 shares, compared to its average volume of 687,887. Acumen Pharmaceuticals has a 12-month low of $0.97 and a 12-month high of $3.60. The company has a fifty day moving average of $2.76 and a two-hundred day moving average of $2.35. The company has a market cap of $180.21 million, a price-to-earnings ratio of -1.24 and a beta of 0.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.07 and a quick ratio of 4.07.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ABOS. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of Acumen Pharmaceuticals in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Wednesday, April 8th. Finally, Wall Street Zen upgraded Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 29th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of Acumen Pharmaceuticals by 45.4% during the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company’s stock valued at $365,000 after acquiring an additional 66,720 shares during the period. Bridgeway Capital Management LLC raised its stake in Acumen Pharmaceuticals by 65.1% during the 3rd quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock worth $325,000 after acquiring an additional 75,000 shares during the period. Jane Street Group LLC lifted its stake in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company’s stock valued at $204,000 after buying an additional 164,866 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Acumen Pharmaceuticals in the second quarter valued at about $160,000. Finally, XTX Topco Ltd bought a new position in shares of Acumen Pharmaceuticals in the fourth quarter worth about $105,000. Institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.